^
CANCER:

Lymphoma

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
No biomarker
Non-Hodgkin’s Lymphoma
valemetostat
Sensitive
:
A1
Daiichi Sankyo Press Release - 1 day - (New A1)
Chr del(11q)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
B
SOHO 2022 - 6 days - (New B)
MYD88 mutation
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive
:
B
SOHO 2022 - 6 days - (New B)
TNFRSF8 positive
Hodgkin Lymphoma
CD30-targeted CAR-T immunotherapy
Sensitive
:
C3
SOHO 2022 - 6 days - (New C3)
No biomarker
Hodgkin Lymphoma
rituximab / hyaluronidase
Sensitive
:
A2
NCCN - 1 week - (New A2)
No biomarker
T Cell Non-Hodgkin Lymphoma
sugemalimab
Sensitive
:
B
CStone Pharma Press Release - 2 weeks - (New B)
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive
:
A1
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Non-Hodgkin’s Lymphoma
brentuximab vedotin
Sensitive
:
A1
ALK positive
Non-Hodgkin’s Lymphoma
crizotinib
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
rituximab
Sensitive
:
A1
No biomarker
Lymphoma
axicabtagene ciloleucel
Resistant
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
tisagenlecleucel-T
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
Rixathon (rituximab biosimilar)
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
cyclophosphamide
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
rituximab
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
orelabrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
orelabrutinib
Sensitive
:
A1
TNFRSF8 positive
Hodgkin Lymphoma
brentuximab vedotin
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
lenalidomide
Sensitive
:
A1
CD20 expression
Non-Hodgkin’s Lymphoma
rituximab-arrx
Sensitive
:
A1
No biomarker
Follicular Lymphoma
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
pembrolizumab
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
carmustine
Sensitive
:
A1
No biomarker
Non-Hodgkin’s Lymphoma
carmustine
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab-abbs
Sensitive
:
A1
No biomarker
Follicular Lymphoma
rituximab-abbs
Sensitive
:
A1
No biomarker
Follicular Lymphoma
Rixathon (rituximab biosimilar)
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab-pvvr
Sensitive
:
A1
No biomarker
Follicular Lymphoma
rituximab-pvvr
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
brentuximab vedotin
Sensitive
:
A1
No biomarker
Follicular Lymphoma
obinutuzumab
Sensitive
:
A1
No biomarker
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive
:
A1
BeiGene Press Release - 1 week - (New A2)